Literature DB >> 816458

Tissue disposition of 3H-actinomycin D (NSC-3053) in the rat, monkey, and dog.

W M Galbraith, L B Mellett.   

Abstract

Tissue concentration of 3H-actinomycin D have been determined in the rat, monkey, and dog after an iv dose of 0.6 mg/m2 body surface area. The drug-tissue half-life was determined for various tissues of the rat, monkey, and dog. A mean drug-tissue half-life of 47 hours was calculated for the tissues of the dog. Exceptions were the testis and brain. Significant concentrations of 3H-actinomycin D failed to accumulate in the brain. Although testis drug concentrations were lower than most other tissues evaluated, the drug-tissue half-life was significantly greater than that of other tissues. In all species studied 3H-actinomycin D was rapidly depleted from serum after iv dosage, with concomitant accumulation of drug in the tissues. 3H-actinomycin D was excreted via the biliary and urinary routes in all species studied. No metabolites of 3H-actinomycin D were detected in the bile or urine of the rat, monkey, or dog with the methods employed. When expressed on a body weight basis, body surface area doses were more than threefold greater in the rat than in the dog. However, the average ratio of concentration X time values (rat C X T/dog C X T) for 11 different tissues of the rat and dog was only 1.3. The results strongly suggest that an equivalent dose of actinomycin D, with dosage based on a body surface area basis, results in nearly equal tissue-drug exposure for most tissues in various mammalian species.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 816458

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


  3 in total

1.  Actinomycin D in the treatment of advanced breast cancer.

Authors:  R A Grimm; H B Muss; D R White; F Richards; M R Cooper; J J Stuart; D V Jackson; P L Barnes; C L Spurr
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

2.  Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.

Authors:  Christopher Walsh; Jennifer J Bonner; Trevor N Johnson; Sibylle Neuhoff; Essam A Ghazaly; John G Gribben; Alan V Boddy; Gareth J Veal
Journal:  Br J Clin Pharmacol       Date:  2016-02-25       Impact factor: 4.335

3.  Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.

Authors:  Christopher R Hill; David Jamieson; Huw D Thomas; Colin D A Brown; Alan V Boddy; Gareth J Veal
Journal:  Biochem Pharmacol       Date:  2012-10-11       Impact factor: 5.858

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.